Endoscopic Retrograde Cholangiopancreatography Market Size

Endoscopic Retrograde Cholangiopancreatography Market size was over USD 3.01 billion in 2024 and is projected to cross USD 14.1 billion by the end of 2037, witnessing more than 12.5% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of endoscopic retrograde cholangiopancreatography is estimated at USD 3.31 billion.

The market growth is mainly owing to the increasing prevalence of pancreatic and biliary diseases, along with the growing geriatric population. According to the American Cancer Society, pancreatic cancer is the third leading cause of cancer-related deaths in the United States. It was noted that about 60,430 people were diagnosed with pancreatic cancer in the year 2021, and about 48,220 people died from the disease. Endoscopic Retrograde Cholangiopancreatography (ERCP) is a minimally invasive medical procedure used to diagnose and treat diseases of the bile and pancreatic ducts.

In addition to this, it involves the insertion of an endoscope through the mouth into the duodenum, where a catheter is then passed through the endoscope and into the bile or pancreatic ducts. ERCP is commonly used to treat conditions such as gallstones, pancreatitis, and biliary obstruction. The prevalence of gallstone disease is estimated to be around 10-15% in the United States, with a higher incidence in women, older adults, and people with obesity. Overall, the increasing prevalence of pancreatic and biliary diseases is contributing to the growth of the ERCP Market as more patients require diagnostic and therapeutic procedures to manage their conditions. Technological advancements in ERCP devices and accessories are also estimated to contribute to the growth of the market over the forecast period.